From lab to bedside

908 Devices has good reason to be based in Boston’s Innovation District. A start-up founded in 2012, the company plans to disrupt the field of chemical analysis with what Vice President Chris Petty calls ‘ridiculously small, and elegantly simple’ mass spectrometry technology.

Photo: From lab to bedside

‘How do you successfully bring analysis to samples rather than samples to laboratories?’ he asks in a blog posted on the company website. ‘908 Devices is working to liberate Mass Spectrometer capabilities from centralised labs’ by reducing cumbersome, complex systems to tiny, revolutionary tools.

At the heart of the rugged and portable systems are molecular traps a thousand times smaller than those in conventional mass spectrometers. Miniaturising traps that can operate closer to atmospheric pressures enables the systems to use dramatically smaller pumps, ionisers, detectors and electronics than large-scale mass spectrometers.

The results are battery-operated handheld chemical analysers reliable enough to meet clinical requirements for the detection and identification of targets, while being robust enough to be immediately available.

The key to success is determining specific uses for the technology. Where conventional, large instruments used in centralised labs today are designed to accommodate a wide variety of applications, 908 Devices is designing what the firm calls ‘tools built for a specific purpose’. Because results are delivered at the point of need, outside centres where specialists generate and interpret data, the new devices must be able to provide answers to non-expert users.

‘We believe passionately that people will do fantastic things when they have these capabilities right in their workspace, or are able to carry them in a pocket,’ Chris Petty predicts.

908 Devices has secured exclusive license to a broad portfolio of patents that enable these simple-to-operate, ultra-compact chemical detection and analysis tools.


Read all latest stories

Related articles


Article •

Mobility is vital for patients and machines

New technological opportunities make it continuously easier to use medical devices anywhere, for in- and out-patient care. The technology has become mobile – and so have the patients. In-patient…


Article • “Taiwan Excellence” at Medica 2022

Sustainable solutions for post-pandemic healthcare

Innovative gastrointestinal imaging, medical panel PCs with hygiene optimisation, smartphone-based diagnostic tools, and sustainable hardware setups: At Medica 2022, manufacturers from Taiwan again…


News • Incubator 2.0

Artificial uterus improves odds for preemies

“An artificial uterus – the incubator 2.0 – will become a reality within 10 years,” says Jasmijn Kok, one of the founders of Juno, a spin-off from the Eindhoven University of Technology,…

Related products

Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Clinical Chemistry

· Alsachim - Dosimmune immunosupressant Alsachim – kit (CE-IVD or RUO)

Alsachim, a Shimadzu Group Company
Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Clinical Chemistry

· Alsachim – Dosimyco immunosupressant reagent kit (RUO)

Alsachim, a Shimadzu Group Company
Biomaneo – NeoSickle solution

Mass Spectrometry

· Biomaneo – NeoSickle solution

Chromalytic –Nitrogen generators for LC-MS

Nitrogen Generators

· Chromalytic –Nitrogen generators for LC-MS

Chromalytic LTD
CliniSys – Anatomical Pathology Laboratory

Information Technology

· CliniSys – Anatomical Pathology Laboratory

CliniSys Deutschland GmbH
CliniSys – Clinical Laboratory

LIS / Middleware / POCT

· CliniSys – Clinical Laboratory

CliniSys Deutschland GmbH
Subscribe to Newsletter